



Original article

Helicobacter pylori resistance to antibiotics in 2014 in France detected by phenotypic and genotypic methods

A. Ducournau, L. Bénéjat, E. Sifré, E. Bessède, P. Lehours, F. Mégraud*

Centre National de Référence des Campylobacters et Helicobacters, Laboratoire de Bactériologie, Université de Bordeaux, Bordeaux, INSERM U853, Bordeaux, France

ARTICLE INFO

Article history:

Received 22 December 2015

Received in revised form

15 March 2016

Accepted 7 June 2016

Available online 23 June 2016

Editor: L. Poirel

Keywords:

23S rDNA mutation

Antimicrobial susceptibility testing

Clarithromycin

Levofloxacin

PYLERA

Tetracycline

ABSTRACT

A large survey of antimicrobial resistance of *Helicobacter pylori* was performed in France in 2014: 984 patients were enrolled by 75 gastroenterologists all over the country. Among the 783 patients who had never received eradication treatment before, 266 (33.9%) were *H. pylori* positive. The strains showed a high rate of clarithromycin resistance (22.2%), moderate rate of resistance to levofloxacin (15.4%) and high rate of resistance to metronidazole (45.9%). In all, 187 patients had received previous treatment, of which 115 were *H. pylori* positive with very high resistance to clarithromycin (73.9%) and metronidazole (78.3%). None of the patients receiving PYLERA (Bismuth salt-Tetracycline HCl-Metronidazole) proton-pump inhibitor developed resistance to tetracycline. A real-time PCR applied to gastric biopsy specimens detected all the cases that were positive by culture as well as 30 additional cases. A good correlation was found between the clarithromycin resistance detected by phenotypic methods and the associated mutations for clarithromycin resistance, which has continued to increase in the last decade but at a lower rate than previously observed. **A. Ducournau, CMI 2016;22:715**

© 2016 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Introduction

Bacterial resistance to antibiotics is an evolving process that requires periodic surveys. Indeed, for *Helicobacter pylori*, resistance to clarithromycin has been shown to be the main cause of failure of the standard triple therapy used for 20 years but now reaching unacceptable levels of failure, i.e. >15% [1].

The introduction of a new treatment, a bismuth-based quadruple therapy namely PYLERA® (a three-in-one capsule containing bismuth salt, tetracycline and metronidazole)—proton-pump inhibitor (PPI), also raises the question of the possible emergence of tetracycline resistance in *H. pylori*.

This study was carried out in France to evaluate the current rate of *H. pylori* resistance to clarithromycin and to five other antibiotics of potential use to treat *H. pylori* infection, in patients who have or have not previously received eradication treatment, and to look for differences according to the defined regions. Particular attention was paid to resistance to tetracycline in patients who received PYLERA.

Materials and methods

Study population

The aim was to select 100 gastroenterologists distributed in five large regions of metropolitan France (Northeast, Northwest, Southeast, Southwest and Paris area). These gastroenterologists were randomly selected from an exhaustive database of gastroenterologists ($n = 2075$) according to the population distribution.

Inclusion was based on patients aged ≥ 18 years, scheduled for an endoscopy, exhibiting a pathology potentially associated with *H. pylori* infection, including those who had failed eradication, with signed informed consent. The aim was to include 1000 patients within a year with a maximum of 20 patients per centre.

This study was approved by the ethical committees under No. 13.470 in September 2013.

Methods used

Data were collected on case report forms and concerned socio-demography, reasons for consultation, use of antibiotics in the previous 30 days, history of infection as well as previous

* Corresponding author. F. Mégraud, Centre National de Référence des Campylobacters et Helicobacters, Laboratoire de Bactériologie, Université de Bordeaux, Bordeaux, INSERM U853, Bordeaux, France.

E-mail address: francis.megraud@chu-bordeaux.fr (F. Mégraud).

eradication attempts including the use of PYLERA-PPI, and endoscopy results.

During upper digestive endoscopy, biopsies were obtained from the antrum and body of the stomach and put together in a Portagerm pylori (bioMérieux, Marcy l'Etoile, France).

The Portagerm pylori was sent, maintained at 4°C, in a van to a central facility, the National Reference Centre for Helicobacters and Campylobacters, in Bordeaux, France, and was most often received the following day.

In the laboratory, the biopsies were ground together (antrum and body) using a manual disposable homogenizer (Eppendorf) in 1 mL of broth and part of the suspension was plated without delay on pylori agar (bioMérieux) and Wilkins Chalgren agar (made in-house) supplemented with 10% human blood and the following antibiotics: cefsulodin, trimethoprim, vancomycin and amphotericin B. The plates were incubated at 37°C in a microaerobic atmosphere (5% O₂, 10% CO₂ and 85% N₂) in a special cabinet, and observed for growth after 2 days and every day for 10 days before being discarded if negative. Colonies suggesting *H. pylori* were tested for oxidase, catalase and urease and observed by microscopy [2].

When positive for *H. pylori*, antimicrobial susceptibility testing was performed according to the following method: preparation of a McFarland 3 equivalent standard suspension; inoculation on a Müller–Hinton agar supplemented with 10% sheep blood; placement of Etests for clarithromycin, amoxicillin and metronidazole, and discs for tetracycline, rifamycin and levofloxacin; and incubation for 48 h at 37°C in a microaerobic atmosphere. Discs were used instead of Etests for tetracycline and rifamycin because of the usual low MIC easily detected in this way. EUCAST criteria were used to determine resistance to clarithromycin, amoxicillin and metronidazole (<http://www.eucast.org>). For the other antibiotics, the following cut-off diameters (mm) were used: tetracycline: resistant <17, susceptible ≥19; rifamycin: resistant <14, susceptible ≥19; and levofloxacin: resistant <17, susceptible ≥20. As no cut-off was recommended for these antibiotics, we performed a study on the distribution of the diameters of 388 strains, which showed a normal distribution confirming the cut-offs chosen for rifampicin and tetracycline. For levofloxacin, MICs were determined by Etest on the strain with intermediate susceptibility. The *H. pylori* strain CCUG 17874 was used for quality control.

In parallel DNA was extracted from the gastric tissue suspension with MagnaPur 96 (Roche Diagnostic, Meylan, France) after proteinase K digestion at 56°C overnight and an in-house real-time PCR developed in the laboratory was used [3]. Sequencing of the target genes was performed in the case of unusual mutation for clarithromycin resistance or for rifamycin resistance and MICs controlled by Etest.

Results

Patient characteristics

In this study, 984 patients were enrolled by 75 gastroenterologists over a 1-year period (February 2014 to February 2015). The median number of patients included per gastroenterologist was 14 (extremes 1–20). Among these patients, 434 (44.1%) were men, and their mean age was 51.5 years ± 15.9. Most of the patients were born in France (718; 73%); the second and third countries of birth were Morocco (54; 5.5%) and Algeria (50; 5%), with the remainder born in 59 different countries worldwide. They were living in 60 different departments out of a total of 96 in metropolitan France. The main symptom warranting endoscopy was epigastric pain in 667 (67.8%). Peptic ulcer was observed at endoscopy in 84 patients (8.5%) and erosions in 203 (20.6%).

Most patients (783; 79.6%) had not received previous *H. pylori* eradication therapy, but 187 (19%) were previously treated, including 57 patients given PYLERA-PPI (30.5%). For 14 patients, it was not known if they had received previous eradication treatment.

Detection of *H. pylori* by culture and antimicrobial susceptibility testing

Culture performed on antral and fundic biopsies of these 984 patients was positive for *H. pylori* in 386 (39.2%) including 266 of the 783 (33.9%) who had never received previous eradication therapy, 115 of the 187 (61.4%) who received this treatment and five for whom the information was not known.

The results of antimicrobial susceptibility testing are presented in Table 1 indicating a high level of clarithromycin resistance (22.2%) among strains from patients who never received any eradication treatment. We did not find any association with gender, or the country of origin (France versus other countries). However, there was an association with age, the patients aged ≥50 years were more likely to harbour clarithromycin-resistant strains than the younger patients (p 0.02).

In contrast, the proportion of resistant strains was comparatively limited for levofloxacin (15.4%). Metronidazole exhibited a very high level of resistance (>40%). No resistance to tetracycline was detected using the disc diffusion method. The three cases of rifamycin resistance were confirmed by sequencing of the *rpoB* gene. The mutations observed were S526T, D530N (already reported [4,5]) and L547F (detected and confirmed by another group in France; J. Raymond, Paris, personal communication). These MICs were ≥32 mg/L.

Secondary resistance corresponding to the cases of patients who already received *H. pylori* eradication treatment, was much higher for clarithromycin and metronidazole, i.e. 73.9% and 78.3%, respectively.

We did not find statistically significant differences in the prevalence of resistance among the five French regions

Detection of *H. pylori* and the mutation associated with macrolide resistance by real-time PCR

The real-time PCR applied to gastric biopsies from the 984 patients was positive for 416 patients (42.3%). This number includes the 386 positive by culture plus 30 new cases (3%).

Globally there were 158 cases with mutations compared with 144 with resistance detected by antimicrobial susceptibility testing, i.e. a slightly higher proportion (37.9% versus 37.7%, respectively).

The mutations found were principally A2142/2143G (150); there were only six A2142C mutations and two A2142T mutations confirmed by sequencing. The MICs of these last two strains were 8

Table 1

Prevalence of *Helicobacter pylori* resistance to antibiotics in France in 2014 according to absence of (primary resistance) or previous (secondary resistance) eradication treatment

	Primary resistance (n = 266)		Secondary resistance (n = 115)	
	No. Resistant	% Resistant (95% CI)	No. Resistant	% Resistant (95% CI)
Clarithromycin	59	22.2 (17.3–27.7)	85	73.9 (64.9–81.7)
Levofloxacin	41	15.4 (11.3–20.3)	17	14.8 (8.9–22.6)
Metronidazole	121	45.9 (39.8–52.1)	90	78.3 (69.6–85.4)
Tetracycline	0	0	0	0
Rifamycin	2	0.7 (0.1–2.7)	1	0.9 (0–4.7)
Amoxicillin	2	0.7 (0.1–2.0)	0	0

and 24 mg/L. The MICs of the strains with an A2142C mutation were all >256 mg/L, whereas the median MIC for those with an A2142/2143G mutation was 8 mg/L. The distribution of the mutations according to the existence or not of a previous eradication treatment is presented in Table 2.

It must be noted that out of the 150 cases where A2142/A2143G mutations were detected, there were 21 with a dual population of resistant and wild-type strains (heteroresistance). This result could be a consequence of the fact that antral and body biopsies were not separated.

Discussion

This survey of antimicrobial resistance of *H. pylori* in France was performed a long time after two previous surveys (18 and 15 years) using the same methodology—a selection of gastroenterologists from all over the country who sent biopsies to a central facility [6].

Standard clarithromycin-based triple therapy has been the recommended treatment in France until recently, but the steady increase in clarithromycin resistance (Fig. 1), which is now >20%, indicates that this therapy should be either tested before being prescribed or avoided, according to the Maastricht-IV guidelines [1]. There is significant macrolide consumption in France, including long-acting macrolides, which are associated with clarithromycin resistance by *H. pylori* [7]. The apparent slower increase of this resistance during the last 15 years could be due to an intense promotion of prudent use of antibiotics. Indeed, macrolide consumption decreased by 27% between 2003 and 2013 in France.

Fluoroquinolone resistance was not tested in our previous surveys because its importance in *H. pylori* treatment only emerged in 2000 [8]. A European study performed in 2008–09 showed a prevalence of 17.6% in France and a good correlation with consumption of these antibiotics in the community [7]. The prevalence of fluoroquinolone resistance in this study was not significantly different from that observed previously.

The results concerning the other antibiotics, with regard to primary resistance, are in line with what were expected, i.e. high resistance to metronidazole, which is known to have a limited clinical impact on *H. pylori* treatment, and resistance to amoxicillin, tetracycline and rifamycin close to nil.

With regard to primary resistance, the high rate of clarithromycin resistance observed is in line with recent publications. *Helicobacter pylori* strains prospectively collected between 2004 and 2007 in Paris and Poitiers for patients not having received previous eradication treatment ($n = 455$) indicated 15.1% of clarithromycin resistance [9]. After failure of a clarithromycin-based triple therapy, the strain becomes resistant in about two-thirds of cases [10].

An important result concerns tetracycline. Indeed, there were 57 patients treated with PYLERA-PPI including 34 who had failed




Fig. 1. Evolution of primary clarithromycin resistance in *Helicobacter pylori* strains isolated from patients in France.

eradication, and none of them became resistant to tetracycline. An increase in resistance was a concern for the regulatory authorities in France, but the situation appears to be different from in the case of macrolides, possibly because three adjacent mutations are required to achieve a high level of resistance [11]. The proportion of patients who received PYLERA-PPI may appear high but this treatment is currently prescribed in about 40% of patients as first-line empiric treatment in France.

With regard to a possible difference in the prevalence of *H. pylori* resistance between regions, the sample size was too small for each region to detect a significant difference.

However, it is interesting to note that the lowest *H. pylori* prevalence was observed in the Southwest of France, as was the case in a study carried out 20 years before [12]. Another interesting point concerns the detection methods for *H. pylori*. Our real-time PCR [3] was applied in parallel to culture on all gastric biopsy specimens. It was able to detect all 386 cases that were culture-positive for *H. pylori*, and in addition 30 cases that were undetected by culture. This result confirms a better sensitivity of real-time PCR compared with culture, probably linked to pre-analytical conditions, i.e. transport and processing in the laboratory, when there is a low bacterial load, given the frailty of *H. pylori*.

With regard to the mutations observed, a large predominance of the transitions (A2142G, A2143G) was found; whereas, the transversion A2142C was found in only six cases and the mutation A2142T in two cases. The A2142T mutation was reported three times in the past [13–15]. Taking into account its position, the high MICs observed and the absence of another cause of resistance, it is the most likely reason for resistance in these cases. In contrast, De Francesco *et al.* found a number of cases where the three common mutations were not present (19/42, 45.2%) but new mutations occurred (notably A2115G, G2141A and A2144T in 14/19) [16]. This finding is difficult to explain. There is a difference in methodology, a TaqMan protocol being used by De Francesco *et al.*, whereas fluorescence resonance energy transfer-melting curve analysis (FRET-MCA) was used in our study. The other explanation could be a difference in the local epidemiology between southern Italy and France.

This current study has the advantage of a good representation of gastroenterologists in the country with a balance between the different regions. Furthermore, patients were not selected from tertiary-care centres where mostly difficult cases are treated but from the patients of mainly private gastroenterologists. Gastric biopsies were also centralized in a common facility, allowing the same method to be carried out by dedicated personnel. Another strength of our current study concerns the methodology associating culture and real-time PCR.

Table 2

Distribution of the point mutations among clarithromycin-resistant *Helicobacter pylori* strains according to existence of a previous treatment

Mutation	'Primary' resistance	'Secondary' resistance	Total
A2143G/A2142G	67 (22.7%)	83 (68.6%)	150 ^a (36.0%)
A2142C	2 (0.6%)	4 (3.3%)	6 (1.4%)
A2142T	1 (0.3%)	1 (0.8%)	2 (0.5%)
Wild-type	225 (76.3%)	33 (27.2%)	258 (62.0%)
Total	295	121	416

Note: The results concerning the mutations presented in this article are slightly different from those in the official interim report of the study due to additional investigations on the nature of the mutations.

^a Includes 21 with a mixed population (wild-type + mutant).

A similar survey was also carried out twice in the past with different gastroenterologists, offering a picture of epidemiological trends for resistance over time.

This study also has some drawbacks. For the prevalence of the infection it is more difficult to draw a conclusion given that the gastroenterologists may have used more or less stringent criteria for inclusion in this study. Furthermore, there were some data missing concerning previous eradication treatment, and it is always possible that information about such treatment may be missed, and the size of the specimen did not allow the detection of differences according to the different regions of the country.

In conclusion, this study shows a continuous increase in macrolide resistance over the years which confirms the recommendation made in the French guidelines [17], and the absence of emergence of resistance to tetracycline despite the use of this antibiotic in the bismuth-based quadruple therapy, namely PYLERA-PPI, available in France since April 2013.

Transparency declaration

Dr. Megraud reports grants from Aptalis Pharma, during the conduct of the study.

Acknowledgements

The authors acknowledge the help of Aptalis Pharma (Grant No. F002343) for funding the study, Umanis for managing the study and of the participating gastroenterologists who registered the patients. This work was presented at the RICAI 2015.

References

- [1] Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, et al. Management of *Helicobacter pylori* infection—the Maastricht IV/ Florence Consensus Report. *Gut* 2012;61:646–64.
- [2] Megraud F. A growing demand for *Helicobacter pylori* culture in the near future? *Ital J Gastroenterol Hepatol* 1997;29:574–6.
- [3] Oleastro M, Menard A, Santos A, Lamouliatte H, Monteiro L, Barthelemy P, et al. Real-time PCR assay for rapid and accurate detection of point mutations conferring resistance to clarithromycin in *Helicobacter pylori*. *J Clin Microbiol* 2003;41:397–402.
- [4] Heep M, Odenbreit S, Beck D, Decker J, Prohaska E, Rieger U, et al. Mutations at four distinct regions of the *rpoB* gene can reduce the susceptibility of *Helicobacter pylori* to rifamycins. *Antimicrob Agents Chemother* 2000;44:1713–5.
- [5] Wang G, Wilson TJ, Jiang Q, Taylor DE. Spontaneous mutations that confer antibiotic resistance in *Helicobacter pylori*. *Antimicrob Agents Chemother* 2001;45:727–33.
- [6] Megraud F. Surveillance de la résistance de *Helicobacter pylori* aux antibiotiques. In: Surveillance nationale des maladies infectieuses 1998–2000. St Maurice, France: Institut de Veille Sanitaire; 2003. p. 327–9.
- [7] Megraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM, et al. *Helicobacter pylori* resistance to antibiotics in Europe and its relationship to antibiotic consumption. *Gut* 2013;62:34–42.
- [8] Cammarota G, Cianci R, Cannizzaro O, Cuoco L, Pirozzi G, Gasbarrini A, et al. Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for *Helicobacter pylori* infection. *Aliment Pharmacol Therapeut* 2000;14:1339–43.
- [9] Raymond J, Lamarque D, Kalach N, Chaussade S, Burucoa C. High level of antimicrobial resistance in French *Helicobacter pylori* isolates. *Helicobacter* 2010;15:21–7.
- [10] Selgrad M, Meissle J, Bornschein J, Kandulski A, Langner C, Varbanova M, et al. Antibiotic susceptibility of *Helicobacter pylori* in central Germany and its relationship with the number of eradication therapies. *Eur J Gastroenterol Hepatol* 2013;25:1257–60.
- [11] Trieber CA, Taylor DE. Mutations in the 16S rRNA genes of *Helicobacter pylori* mediate resistance to tetracycline. *J Bacteriol* 2002;184:2131–40.
- [12] Broutet N, Marais A, Lamouliatte H, de Mascarel A, Samoyeau R, Salamon R, et al. *cagA* Status and eradication treatment outcome of anti-*Helicobacter pylori* triple therapies in patients with nonulcer dyspepsia. *J Clin Microbiol* 2001;39:1319–22.
- [13] van Doorn LJ, Glupczynski Y, Kusters JG, Megraud F, Midolo P, Maggi-Solca N, et al. Accurate prediction of macrolide resistance in *Helicobacter pylori* by a PCR line probe assay for detection of mutations in the 23S rRNA gene: multicenter validation study. *Antimicrob Agents Chemother* 2001;45:1500–4.
- [14] Kuwahara H, Kariu T, Fang J, Maeda H. Generation of drug-resistant mutants of *Helicobacter pylori* in the presence of peroxydinitrite, a derivative of nitric oxide, at pathophysiological concentration. *Microbiol Immunol* 2009;53:1–7.
- [15] Taylor DE. Pathophysiology of antibiotic resistance: clarithromycin. *Can J Gastroenterol / J canad gastroenterol* 2000;14:891–4.
- [16] De Francesco V, Zullo A, Giorgio F, Saracino I, Zaccaro C, Hassan C, et al. Change of point mutations in *Helicobacter pylori* rRNA associated with clarithromycin resistance in Italy. *J Med Microbiol* 2014;63:453–7.
- [17] Lamarque D, Burucoa C, Courillon-Mallet A, de Korwin JD, Delchier JC, Fauchère JL, et al. Revised French recommendations on the management of *Helicobacter pylori* infection. *Hepato-Gastro d'Oncol Dig* 2012;19:475–502.